Aspergillus galactomannan antigen detection, bronchoalveolar lavage (BAL) or serum-13548

Test info

Aspergillus galactomannan antigen detection, bronchoalveolar lavage (BAL) or serum
A. fynugatys

Patients diagnosed with chronic granulomatous disease and/or Job's syndrome may yield a reduced detection of galactomannan


2.0 mL
0.35 mL
Submission of the minimum volume does not allow for repeat testing
  • Collect specimen using aseptic technique
  • Mix sample by gentle inversion, 5 times
  1. Allow sample to clot for a minimum of 30 minutes
  2. Spin within two (2) hours of sample collection

AVOID opening the specimen after collection to prevent contamination with fungal spores and/or bacteria present in the environment ( transport in sealed tubes).


Gold serum separator (SST) tube


Bronchoalveolar lavage (BAL)

Red serum vial/tube, 5 mL

BAL - Sterile container

2.0 mL

Sterile container



Refrigerated (unopened) - 5 days

Refrigerated (Opened) - 48 hours

Frozen - 5 months

     Freeze/thaw cycle: Stable x4

Ambient - NO


Refrigerated (Unopened) - 24 hours

Frozen - 5 months

     Freeze/thaw cycle: Stable x4

Ambient - NO

  • Unlabeled specimen or name discrepancy between specimen and test request form
  • Blood collected in collection tubes other than those specified
  • Grossly hemolyzed, lipemic, or icteric blood specimens
  • Respiratory specimens other than BAL
  • Inadequate specimen volume
  • Specimen received after the specified time or improperly stored/transported
  • Specimen source other than BAL or serum
  • Specimens submitted in non-sterile containers


LabCorp Burlington (183805): R-LC
Mo, We, Fr
2 - 5 days

Enzyme immunoassay (EIA)

Clinical and Interpretive info


0.00 - 0.49 Index


Reduced assay sensitivity may occur in patients receiving concomitant antifungal therapy. Penicillium species, Alternaria species, Paecilomyces species, Geotrichum species, and Histoplasma species have demonstrated reactivity with the monoclonal antibodies used in the assay and may, therefore, yield a positive test result.

Positive results in patients with no clinical signs of disease have been reported, especially in young children. Most of these are considered to be false positives. Young children may have a positive assay result due to the presence of galactofuranaase contained in various foods (cereals) and milk. Patients receiving piperacillin/tazobactam or semisynthetic beta-lactamase therapy may have false-positive results. False-positive results may also occur with use of PLASMA-LYTE(TM) for either intravenous hydration or BAL specimen collection.

Submission of specimens poured off, or specimens sent in non-sterile containers is not recommended as this can lead to false positive results.


Result 62467-6